07:42 AM EDT, 05/07/2025 (MT Newswires) -- Teva Pharmaceutical Industries ( TEVA ) reported Q1 non-GAAP earnings Wednesday of $0.52 per diluted share, up from $0.48 a year earlier.

Four analysts polled by FactSet expected $0.47.

Net revenue for the quarter ended March 31 was $3.89 billion, up from $3.82 billion a year earlier.

Analysts surveyed by FactSet expected $4.06 billion.

The company said its updated full-year 2025 guidance considered the tariff and trade environment as of Wednesday.

Teva now expects 2025 non-GAAP diluted EPS of $2.45 to $2.65, compared with its previous guidance of $2.35 to $2.65. Analysts surveyed by FactSet expect $2.59. Full-year 2025 revenue is now expected to range from $16.8 billion to $17.2 billion, from its previous guidance of $16.8 billion to $17.4 billion. Analysts polled by FactSet expect $17.51 billion.

The company's shares were up 2.1% in recent premarket activity Wednesday.